The vaccine primes neoantigen-specific T cells via antigen presentation by APCs; the expanded T cells kill cells presenting the specific neoantigen peptides (via MHC I/II) through perforin/granzyme or Fas–FasL. HLA-DP expression itself is not the cytotoxic target.